For a woman with a worrying symptom, the path to a cancer answer often runs through an invasive test - a scan, a biopsy, a procedure that is uncomfortable, sometimes painful, and frequently, in the end, unnecessary. A blood test now being adopted by NHS trusts is built to spare tens of thousands of those exams by doing the sorting first.
The test is called PinPoint, from the Leeds company PinPoint Data Science. It reads about 30 markers in a routine blood sample and produces a cancer-risk score for patients whom a GP has referred with concerning symptoms [1]. In an NHS evaluation of 16,481 patients across around 170 Yorkshire practices - 2,953 of whom turned out to have suspected cancer - the test reached roughly 99 percent accuracy: it correctly flagged 99.1 percent of cancers as elevated or high-risk, and for the group it scored lowest-risk, its negative predictive value was 99.8 percent [1].
The figure that matters most to patients is the second one. A test that can reliably identify who is genuinely low-risk lets the system stop sending those people for invasive follow-ups they do not need - and analysts estimate it could spare tens of thousands of women, in particular, from unnecessary ultrasounds and biopsies on gynaecological cancer pathways [1]. Mid Yorkshire Teaching NHS Trust and Leeds Teaching Hospitals NHS Trust have begun using it. The cost is about 30 pounds a test [1].
None of this replaces a diagnosis; it triages who needs one, faster and with less ordeal. A 30-pound blood test that can safely wave through the people who do not have cancer, and speed the people who do toward care, is the kind of quiet infrastructure that rarely makes headlines and changes a great many days for the better [1][2].
